Project Grant R01AI184568

Award Date 7/1/24
Completion Date 6/30/29
Dollars Obligated $1.5M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $140,256 to Washington University to conduct research on how the tuberculosis (TB) pathogen Mycobacterium tuberculosis (MTB) promotes its survival in neutrophils. The key objectives are to: 1) Investigate how the MTB type VII secretion system (T7SS), specifically the ESX-1 component, affects neutrophil phagosome...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,503,349 to the University of Arkansas for Medical Sciences (UAMS) to study the ontogeny (origin) and metabolism of lung alveolar macrophages and their role in tuberculosis (TB) infection. The overarching goal is to understand how the origin and metabolic pathways of these immune cells impact their...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, is funding research to investigate how Mycobacterium tuberculosis (MTB) infection triggers host cell death mechanisms. The $819,998 award to The Regents of the University of California, San Francisco (UCSF) aims to elucidate the regulatory roles of autophagy factors TAX1BP1 and optineurin in modulating MTB pathogenesis and host cell death...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $278,390.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on determining the value of the ESAT-6 antigen in Mycobacterium tuberculosis (MTB) infection and vaccines. The project aims to understand whether ESAT-6-specific CD4 T cell responses are beneficial, detrimental, or neutral in MTB infection,...
This federal Project Grant award of $489,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the establishment of a novel human lung alveolar epithelial cell organoid model to study Mycobacterium tuberculosis (MTB) infection and host innate immune responses. The primary objectives are to develop a physiologically relevant in vitro platform using human bronchoalveolar lavage fluid (BALF) to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $721,194 to Florida State University to conduct research on the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: (1) investigate the structural and functional roles of the FtsQ-FtsZ protein interaction; (2) characterize the structure,...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...

UNDERSTANDING EARLY MACROPHAGE-T CELL INTERACTIONS, SLAMF1, AND IMMUNITY TO TB - SUMMARY MYCOBACTERIUM TUBERCULOSIS (MTB) CAUSES ONE OF THE WORLD'S MOST DEADLY INFECTIONS. INITIALLY, MTB INFECTS ALVEOLAR MACROPHAGES (AMS), AND OVER TIME, IT DISSEMINATES INTO MONOCYTES, INTERSTITIAL AND RECRUITED MACROPHAGES, AND NEUTROPHILS. ONCE AN ADAPTIVE IMMUNE RESPONSE DEVELOPS, CD4 T CELLS PROMOTE THE ABILITY OF MACROPHAGES TO CONTROL MTB, ALTHOUGH THE MECHANISMS BY WHICH CD4 T CELLS CONFER PROTECTION ARE NOT FULLY UNDERSTOOD. IN ADDITION TO SECRETING DIFFUSIBLE CYTOKINES LIKE IFN-, COGNATE INTERACTIONS BETWEEN CD4 T CELLS AND MTB-INFECTED MACROPHAGES ARE IMPORTANT FOR MTB CONTROL. AT THE SAME TIME, MTB UNDERMINES MACROPHAGE-T CELL INTERACTIONS. THUS, OPTIMIZING MACROPHAGE-T CELL INTERACTIONS MAY BE AN EFFECTIVE STRATEGY TO GENERATE PROTECTION. HOWEVER, UNTIL NOW, THERE HAS NOT BEEN A WAY TO DETERMINE WHICH MACROPHAGES HAVE PRESENTED ANTIGEN TO CD4 T CELLS. WE DISCOVERED THAT MTB-INFECTED MACROPHAGES INDUCE THE CELL SURFACE MOLECULE SLAMF1 (SLAM/CD150) IN RESPONSE TO COGNATE INTERACTIONS WITH CD4 T CELLS. WE SHOW THAT SLAMF1 DISTINGUISHES MACROPHAGES THAT ARE INFECTED AND HAVE INTERACTED WITH T CELLS FROM UNINFECTED, BYSTANDER MACROPHAGES THAT EXPERIENCE THE SAME CYTOKINE MILIEU, BOTH IN VIVO IN MICE AND EX VIVO IN MACROPHAGE-T CELL CO-CULTURES. MOREOVER, WE FOUND THAT SLAMF1-/- MICE HAVE HIGHER MTB BURDEN IN THE LUNGS, ENHANCED INFLAMMATORY CELL RECRUITMENT, ALTERED CYTOKINE RESPONSES, AND DIE EARLIER FROM TB COMPARED TO WT MICE. MACROPHAGE SLAMF1 EXPRESSION ALSO CORRELATES WITH PROTECTION IN NON-HUMAN PRIMATES. SLAMF1 IS A TYPE I TRANSMEMBRANE RECEPTORS THAT IS FOUND EXCLUSIVELY ON HEMATOPOIETIC CELLS. SLAMF1 MEDIATES CELL-CELL SIGNALING THROUGH HOMOTYPIC SLAMF1-SLAMF1 INTERACTIONS, AND IT CAN ALSO DIRECTLY BIND BACTERIA. WE HYPOTHESIZE THAT WHEN MACROPHAGES PRESENT ANTIGEN TO CD4 T CELLS, MACROPHAGES TO UPREGULATE SLAMF1, WHICH PROMOTES CONTROL OF MTB IN THE MACROPHAGES BY ACTIVATING REACTIVE OXYGEN SPECIES (ROS) AND AUTOPHAGY-RELATED PATHWAYS. ACTIVATED T CELLS ALSO EXPRESS SLAMF1, AND WE PROPOSE THAT SLAMF1 SIGNALING FROM MACROPHAGES TO THE T CELLS PROMOTES RESOLUTION OF INFLAMMATION. THUS, ACTIVATING SLAMF1 MAY IMPROVE MTB CONTROL WHILE REDUCING IMMUNOPATHOLOGY. HERE, MAKING USE OF SLAMF1FL/FL CONDITIONAL KNOCK-OUT MICE THAT WE MADE, WE WILL DETERMINE THE CELL TYPE SPECIFIC ROLES OF SLAMF1 DURING TB. USING TRANSWELL ASSAYS TO STUDY MACROPHAGE-T CELL INTERACTIONS, WE WILL ESTABLISH WHETHER MACROPHAGE-CD4 T CELL INTERACTIONS AND SLAMF1 CONTRIBUTE TO MTB CONTROL IN HUMAN AND MURINE MACROPHAGES. WE WILL ESTABLISH WHETHER CD4 T CELLS AND SLAMF1 DRIVE MACROPHAGE ROS PRODUCTION AND AUTOPHAGY, WHETHER THIS PATHWAY IS UNDERMINED BY MTB VIRULENCE FACTORS, AND WHETHER IT CAN BE AUGMENTED BY SMALL MOLECULES AND SLAMF1 AGONISTS. FINALLY, MAKING USE OF SLAMF1 REPORTER MICE THAT WE MADE, WE WILL ELUCIDATE THE DYNAMICS OF EARLY MACROPHAGE-T CELL INTERACTIONS DURING MTB INFECTION, AND HOW THESE INTERACTIONS ARE ALTERED BY VACCINES, TRAINED IMMUNITY, AND CONTAINED INFECTION. THESE STUDIES WILL YIELD MECHANISTIC INSIGHT INTO EARLY EVENTS IN HOST IMMUNITY TO TB AND SUPPORT THE DEVELOPMENT OF NOVEL THERAPIES AND VACCINES TO GENERATE STERILIZING IMMUNITY.

Posted 7/1/24, 12:00 AM